VEGFA and Hypertension: Sorafenib, an inhibitor targeting FLT3 approved for children with AML, may determine significant hypertension and left ventricular systolic dysfunction, particularly when combined with anthracyclines, due to its off-target activity on the vascular endothelial growth factor [45].